The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment
Open accessAbstract
Protein-based therapeutics have been revolutionizing the oncology space since they first appeared in the clinic two decades ago. Unlike traditional small-molecule chemotherapeutics, protein biologics promote active targeting of cancer cells by binding to cell surface receptors and other markers specifically associated with or overexpressed on tumors versus healthy tissue. While the first approved cancer biologics were monoclonal antibodies, the burgeoning field of protein engineering is spawning research on an expanded range of protein formats and modifications that allow tuning of properties such as target binding affinity, serum half-life, stability, and immunogenicity. In this review, we highlight some of these strategies and provide examples of modified and engineered proteins under development as preclinical and clinicalstage drug candidates for treating cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Biopharmaceutical benchmarks 2014
Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Therapeutic protein aggregation: mechanisms, design, and control
Roberts, C. J. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.05.005 · Cited by 455
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
A strategy for risk mitigation of antibodies with fast clearance
Hötzel, I., Theil, F.-P., Bernstein, L. J., Prabhu, S., Deng, R., Quintana, L., Lutman, J., Sibia, R., Chan, P., Bumbaca, D., et al. (2012) · mAbs · doi:10.4161/mabs.22189 · Cited by 245
Zeidler, R., Mysliwietz, J., Csánady, M., Walz, A., Ziegler, I., Schmitt, B., Wollenberg, B., & Lindhofer, H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1237 · Cited by 189
Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor (FcRn) Binding
Andersen, J. T., Dalhus, B., Viuff, D., Ravn, B. T., Gunnarsen, K. S., Plumridge, A., Bunting, K., Antunes, F., Williamson, R., Athwal, S., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.549832 · Cited by 167
Cited by
Zhu, Q., Chen, X., Xu, X., Zhang, Y., Zhang, C., & Mo, R. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201707371 · Cited by 105
Beygi, M., Oroojalian, F., Hosseini, S. S., Mokhtarzadeh, A., Kesharwani, P., & Sahebkar, A. (2023) · Progress in Materials Science · doi:10.1016/j.pmatsci.2023.101209 · Cited by 32
RetractedLi, J., Tuma, J., Han, H., Kim, H., Wilson, R. C., Lee, H. Y., & Murthy, N. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102118 · Cited by 16
Metadata
- Authors
- Kintzing, J. R., Filsinger Interrante, M. V., & Cochran, J. R.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 37
- Issue
- 12
- Pages
- 993-1008
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2552023306
- Cited by
- 191
- References
- 10
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment. https://app.cochat.ai/papers/10.1016/j.tips.2016.10.005
- The paper
- Kintzing, J. R., Filsinger Interrante, M. V., & Cochran, J. R. (2016). Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2016.10.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.